Pulmonary Rehabilitation in COVID-19 Patients
1 other identifier
observational
300
1 country
1
Brief Summary
It was aimed to evaluate the respiratory functions of patients who were given respiratory rehabilitation, bed positioning and early mobilization, and the time of leaving the hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedFirst Submitted
Initial submission to the registry
March 27, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2021
CompletedFirst Posted
Study publicly available on registry
April 6, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2021
CompletedApril 6, 2021
April 1, 2021
3 months
March 27, 2021
April 3, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
GLASKOW COMA SCALE
The scale was described in 1974 by Graham tesdale and Bryan Jenett as a way to communicate of patients with an acute brain injury. A person's GCS score can range from 3 (completely unresponsive) to 15 (responsive). This score is used to guide immediate medical care after a brain injury (such as a car accident) and also to monitor hospitalized patients and track their level of consciousness. The glasgow coma scale is often used to help define the severity of TBI. Mild head injuries are generally defined as those associated with a glasgow coma scale score of 13-15, and moderate head injuries are those associated with a glasgow coma scale score of 9-12. A glasgow coma scale score of 8 or less defines a severe head injury.
change from baseline glaskow coma scale at 1 months
mMRC dyspnea scale
THe mMRC dsypnea scale quantifies disability attributable to breathlessness and is useful for charecterizing baseline dyspnea in patients with respiratory disease. describes baseline dyspnea but does not accurately quantify response to treatment of chornic obstructive pulmonary disease (COPD).
change from baseline at 1 month
Secondary Outcomes (3)
SpO2
change from baseline at 1 month
carbon dioxide (CO2)
change from baseline at 1 month
cardiac output test
change from baseline at 1 month
Eligibility Criteria
patients in Hospital's service
You may qualify if:
- Being over 18 years old
- Those who have been hospitalized since 11.01.2020
- Those who have been consulted to the physical therapy clinic since 11.01.2020
You may not qualify if:
- Fever ˃38.0 °
- Initial consultation time ˂7 days
- In those with 3 days from the onset of the disease to shortness of breath Chest radiographic scans showing 50% progression within 24 to 48 hours
- With Spo2 level ≤95%
- Resting blood pressure ˂90 / 60 (1mmHg = 0.133kPa) or ˃140 / 90mmHg. 100 heart rate per minute Those with moderate and / or severe heart disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bakirkor Dr. Sadi Konuk Research and Training hospital
Istanbul, 34147, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
meltem vural
Bakırkoy Dr. Sadi Konuk Training and Research Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
March 27, 2021
First Posted
April 6, 2021
Study Start
January 1, 2021
Primary Completion
April 1, 2021
Study Completion
May 1, 2021
Last Updated
April 6, 2021
Record last verified: 2021-04